Form 4: Beam Therapeutics CEO John Evans Sells Shares to Cover Tax Obligations

Beam Therapeutics CEO John M. Evans sold 30,663 shares of common stock on April 1, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On April 1, 2025, John M. Evans, CEO of Beam Therapeutics Inc., sold 30,663 shares of common stock at a weighted average price of $18.3506 per share.
• The sale was executed to cover tax withholding obligations upon the vesting of restricted stock units granted under the company's 2019 Equity Incentive Plan.
• The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on May 19, 2023.
• Following the transaction, Evans directly owns 986,249 shares of Beam Therapeutics common stock.
• Evans also indirectly owns 103,000 shares through the John M. Evans, III 2018 Irrevocable Trust.
• Additionally, Evans acquired 753 shares under the BEAM Amended and Restated 2019 Employee Stock Purchase Plan on March 31, 2025.

Sentiment

Score: 6

Explanation: Neutral sentiment as the transaction appears to be a routine sale for tax purposes under a pre-existing trading plan. It doesn't necessarily indicate a lack of confidence in the company.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating it was planned well in advance and not based on current market conditions or insider information.
• Evans acquired 753 shares under the Employee Stock Purchase Plan on March 31, 2025, showing continued investment in the company.

Negatives

• The sale of shares, even for tax purposes, could be perceived negatively by some investors, although it is a common practice.

Risks

• While the sale was for tax obligations, large sales by executives can sometimes create short-term downward pressure on the stock price.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies, often related to compensation and tax planning. The use of a pre-arranged Rule 10b5-1 trading plan is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• Executive compensation packages often include stock options and restricted stock units, which vest over time.
• Sales to cover tax obligations are a typical part of managing these equity-based compensation components.
• Rule 10b5-1 plans are widely used by executives at companies like CRISPR Therapeutics and Editas Medicine to manage their stock transactions in a compliant manner.

Stakeholder Impact

• The stock sale could have a minor short-term impact on shareholders due to potential downward pressure on the stock price.
• The sale does not appear to have a significant impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Beam Therapeutics, John Evans, stock sale, Form 4, insider trading, Rule 10b5-1, tax obligations, equity incentive plan, employee stock purchase plan